This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Tirzepatide reduced HbA1c by 1% and body weight by 3.95 kg without increasing hypoglycemia risk.
Why it matters
This research highlights a new effective treatment option for patients with uncontrolled type 2 diabetes, addressing both glucose control and weight management.
How the study worked
The study is a systematic review and meta-analysis of eleven randomized controlled trials.
What this study cannot tell us
The review is based on existing trials, which may vary in quality and design, potentially affecting the generalizability of the findings.
Read the original research
Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.
Frontiers in endocrinology, 13, 920541
Citation
Lisco, Giuseppe; De Tullio, Anna; Disoteo, Olga; De Geronimo, Vincenzo; Piazzolla, Giuseppina; De Pergola, Giovanni; Giagulli, Vito Angelo; Jirillo, Emilio; Guastamacchia, Edoardo; Sabbà, Carlo; Triggiani, Vincenzo. (2022). Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.. Frontiers in endocrinology, 13, 920541. https://doi.org/10.3389/fendo.2022.920541